Sex‐related differences in hospital admissions attributed to adverse drug reactions in the Netherlands

Rodenburg, Eline M.; Stricker, Bruno H. Ch.; Visser, Loes E.

doi:10.1111/j.1365-2125.2010.03811.x

Cited by 78 publications

(60 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…117 Side effects of antihypertensive therapy tend to be encountered with a higher degree of frequency in women than men. Diuretic-induced disturbances of electrolyte concentration are seen more frequently in women, 118,119 as is angiotensinconverting enzyme inhibitor-induced cough and calcium channel blocker (CCB)-related dependent edema.…”

Section: Sex Bp Antihypertensive Treatment and Achieving Bp Goalsmentioning

confidence: 99%

Guidelines for the Prevention of Stroke in Women

Bushnell¹,

McCullough²,

Awad³

et al. 2014

Stroke

788

414

View full text Add to dashboard Cite

1545Purpose-The aim of this statement is to summarize data on stroke risk factors that are unique to and more common in women than men and to expand on the data provided in prior stroke guidelines and cardiovascular prevention guidelines for women. This guideline focuses on the risk factors unique to women, such as reproductive factors, and those that are more common in women, including migraine with aura, obesity, metabolic syndrome, and atrial fibrillation. Results-We provide current evidence, research gaps, and recommendations on risk of stroke related to preeclampsia, oral contraceptives, menopause, and hormone replacement, as well as those risk factors more common in women, such as obesity/metabolic syndrome, atrial fibrillation, and migraine with aura. Conclusions-To more accurately reflect the risk of stroke in women across the lifespan, as well as the clear gaps in current risk scores, we believe a female-specific stroke risk score is warranted. (Stroke. 2014;45:1545-1588.)

show abstract

Section: Sex Bp Antihypertensive Treatment and Achieving Bp Goalsmentioning

confidence: 99%

Guidelines for the Prevention of Stroke in Women

Bushnell¹,

McCullough²,

Awad³

et al. 2014

Stroke

788

414

View full text Add to dashboard Cite

show abstract

“…Epidemiologic studies in large population samples have shown an increased risk of adverse drug effects among females 31,32 however, most MDA dosages in LF elimination programs have been defined based on population parameters of weight-for-age 13,14,33,34 and have not considered sex variations in weight in terms of the tolerability of antifilarial drugs. The data from this study suggest that adjusting dosage schedules in MDA by genders may reduce the occurrence of ADRs, primarily by reducing the number of ADRs in the female population.…”

Section: Discussionmentioning

confidence: 99%

Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil

Lima

Medeiros

Santos

et al. 2012

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:The Global Programme to Eliminate Lymphatic Filariasis was launched with the goal of eliminating this disease via the annual mass drug administration (MDA) of a single dose of antifilarial drugs. Adverse drug reactions following MDA are a major factor of poor treatment adherence in several countries. This study assessed the occurrence of adverse drug reactions (ADRs) following the first round of mass treatment in two communities treated with different dosages of diethylcarbamazine (DEC) in the City of Recife, Brazil. Methods: Population-based cross-sectional surveys were conducted in a random sample of the population living in both communities (Areas I and II). The dose of DEC recommended by the WHO (6mg/kg) was calculated based on the individual's weight-for-age. In Area II, weight differences between the genders were also considered when determining dosage. Data were obtained through interviews conducted in the first 12 to 48h and on the 5 th day after MDA during household visits. Results: A total of 487 and 365 individuals were interviewed in Areas I and II, respectively. The prevalence of ADRs in Area I (23.6; 95%CI: 19.1-29.5) was higher than in Area II (16.2; 95%CI:11.9-21.5)(p=0.0078). The prevalence of ADRs among females was higher than in males in Area I (p=0.0021). In Area II, no significant difference between the genders was observed (p=0.1840). Age was not associated with ADRs in either area. Conclusions: Adjusting MDA dosage schedules according to weight-for-age and sex may be may contribute to reduce the occurrence of adverse drug reactions in the population.

show abstract

“…Both frequency and character of ADE in women may depend on the drug type (Rodenburg et al 2011). For example, iatrogenic osteoporosis and fractures can be induced by corticosteroids, thiazolidinedione, and aromatase inhibitors.…”

Section: Females' Vulnerability Respect To Specific Classes Of Drugsmentioning

confidence: 99%

Sex and Gender in Adverse Drug Events, Addiction, and Placebo

Franconi

Campesi

Occhioni

et al. 2012

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Sex-gender-based differences in response to pharmaceutical treatments are still under evaluation but evidence already exists regarding the impact of sex-gender-related differences on drug safety profile, drug abuse/addiction, and placebo effects. For a number of drugs it is well recognized that a sex-gender dimorphic profile in terms of drug adverse effects exists and appears to be more frequent and severe in women than in men. However, it is not well known whether this is due to pharmacodynamic or pharmacokinetic differences. Indeed the optimization of therapy requires that attention is paid to single sex-gender. Numerous pharmacokinetic, pharmacodynamic, and sociocultural differences between women and men in drug abuse have been described. Here we focus on sex-gender differences in alcoholism and nicotine addiction. The relevance of sex and gender differences in addiction appear to be relevant. Specific programs aimed to address addicted women's specific needs (child care, pregnancy, housing, and violence and others) are recommended. Finally, this article discusses the possible effect of sex-gender on placebo response in the light of the more significant recent literature evidencing that studies are urgently required in order to better understand the role of sex-gender on placebo mechanism and its impact on randomized clinical trials outcomes.

show abstract

Sex‐related differences in hospital admissions attributed to adverse drug reactions in the Netherlands

Cited by 78 publications

References 42 publications

Guidelines for the Prevention of Stroke in Women

Guidelines for the Prevention of Stroke in Women

Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil

Sex and Gender in Adverse Drug Events, Addiction, and Placebo

Contact Info

Product

Resources

About